Literature DB >> 28982957

Macular pigment is associated with glare-affected visual function and central visual field loss in glaucoma.

We Fong Siah1, Colm O'Brien1,2, James J Loughman3,4.   

Abstract

AIM: To evaluate the relationship between macular pigment optical density (MPOD) and glare disability in open-angle glaucoma.
METHODS: A cross-sectional analysis of baseline data (88 subjects; median age, 67 (range 36-84) years) collected during the Macular Pigment and Glaucoma Trial (ISRCTN registry number: 56985060). MPOD at 0.25°, 0.5° and 1° of retinal eccentricity was measured using customised heterochromatic flicker photometry. Mesopic contrast sensitivity with glare (mCSg), photostress recovery time (PRT) and self-reported glare symptoms were evaluated. Fourier-domain optical coherence tomography was used to analyse ganglion cell complex (GCC) and identify foveal involvement.
RESULTS: Low spatial frequency (f) mCSg was significantly correlated with MPOD at 0.25°(3 cycles per degree (cpd): r=0.25, p=0.04) and 0.5° (3 cpd: r=0.23, p=0.04) of retinal eccentricity. Those with foveal GCC loss exhibited lower MPOD, had worse low spatial fmCSg (1.5 cpd and 3 cpd, p=0.02 each) and prolonged PRT (p=0.02) in comparison with those without foveal involvement. The depth of central 10° field loss was related to MPOD at all eccentricities (p<0.01 for all). Those who reported glare symptoms had a significantly lower MPOD at all retinal eccentricities (0.25° and 1°: p=0.05 each; 0.5°: p=0.04), including those with foveal involvement (0.25°: p=0.05; 0.5°: p<0.01; 1°: p=0.01).
CONCLUSIONS: Macular pigment level may be an important consideration among those experiencing disability glare in glaucoma, including those with foveal involvement. TRIAL REGISTRATION NUMBER: ISRCTN56985060, Post-results. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  field of vision; glaucoma; macula; psychophysics

Mesh:

Substances:

Year:  2017        PMID: 28982957     DOI: 10.1136/bjophthalmol-2017-310215

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  6 in total

1.  Fingertip-Measured Skin Carotenoids and Advanced Glycation End Product Levels in Glaucoma.

Authors:  Yoichi Kadoh; Yuji Takayanagi; Junichi Sasaki; Masaki Tanito
Journal:  Antioxidants (Basel)       Date:  2022-06-09

2.  Evaluation of the association between macular damage and disability glare in patients with advanced glaucoma.

Authors:  Yun Hsia; Tsing-Hong Wang; Jehn-Yu Huang; Chien-Chia Su
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-02-22       Impact factor: 3.535

3.  Macular Pigment and Visual Function in Patients With Glaucoma: The San Diego Macular Pigment Study.

Authors:  Fábio B Daga; Nara G Ogata; Felipe A Medeiros; Rachel Moran; Jeffrey Morris; Linda M Zangwill; Robert N Weinreb; John M Nolan
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-09-04       Impact factor: 4.799

4.  Macular Pigment and Open-Angle Glaucoma in the Elderly: The Montrachet Population-Based Study.

Authors:  Louis Arnould; Alassane Seydou; Christine Binquet; Pierre-Henry Gabrielle; Chloé Chamard; Lionel Bretillon; Alain M Bron; Niyazi Acar; Catherine Creuzot-Garcher
Journal:  J Clin Med       Date:  2022-03-25       Impact factor: 4.241

5.  Macular Pigment Response to Lutein, Zeaxanthin, and Meso-zeaxanthin Supplementation in Open-Angle Glaucoma: A Randomized Controlled Trial.

Authors:  James Loughman; Ekaterina Loskutova; John S Butler; We Fong Siah; Colm O'Brien
Journal:  Ophthalmol Sci       Date:  2021-07-11

Review 6.  Carotenoids in the Management of Glaucoma: A Systematic Review of the Evidence.

Authors:  Drake W Lem; Dennis L Gierhart; Pinakin Gunvant Davey
Journal:  Nutrients       Date:  2021-06-06       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.